Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 913836-04-1 | MDL No. : | MFCD08689540 |
Formula : | C9H9BN2O3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | GXJXMCCAPBQQHR-UHFFFAOYSA-N |
M.W : | 203.99 | Pubchem ID : | 44119380 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 11 |
Fraction Csp3 : | 0.11 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 54.53 |
TPSA : | 79.38 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.03 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 0.72 |
Log Po/w (WLOGP) : | -0.28 |
Log Po/w (MLOGP) : | -0.02 |
Log Po/w (SILICOS-IT) : | -0.26 |
Consensus Log Po/w : | 0.03 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.97 |
Solubility : | 2.19 mg/ml ; 0.0107 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.97 |
Solubility : | 2.21 mg/ml ; 0.0108 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.67 |
Solubility : | 0.439 mg/ml ; 0.00215 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.71 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
37% | With N-ethyl-N,N-diisopropylamine In 1,4-dioxane; water at 90℃; | DIEA (50 μ, 0.288 mmol) was added to Pd(Ph3P)4 (6 mg, 4.79 μιηο), -(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5- yl trifluoromethanesulfonate (40 mg, 0.096 mmol), 3-(5-methyl-l,3,4-oxadiazol-2- yl)phenylboronic acid (29 mg, 0.144 mmol). Dioxane (1 mL) and water (200 μΚ) was added at rt. The reaction was heated to 90 °C overnight. The mixture was cooled and purified by preparative reverse phase HPLC on a CI 8 column using a suitably buffered H20/CH3CN gradient, and concentrated to give the titled compound (16 mg, 37%). 1H NMR (500 MHz, DMSO-d6) δ ppm 8.49 - 8.56 (1 H, m), 8.24 (1 H, s), 7.98 - 8.05 (4 H, m), 7.93 (1 H, s), 7.79 - 7.83 (1 H, m), 7.68 - 7.76 (2 H, m), 7.41 (2 H, t, J=8.70 Hz), 2.87 (3 H, d, J=4.58 Hz), 2.62 (3 H, s). LC-MS retention time: 1.41 min; m/z (MH-): 426. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XB ridge 5u CI 8 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nM. The elution conditions employed a flow rate of 5 ml/min , a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H20 / 10 mM ammonium acetate and solvent B was 5% H20 / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a Micromass Platform for LC in electrospray mode. Additonal HPLC method: Solvent A = 5% CH3CN/95%H2O/0.1% TFA, Solvent B = 95% CH3CN/5% H2O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, Rt = 12.96 min, purity = 95% ; Column: Waters Xbridge Phenyl column 4.6 x 150 mm, 3.5 mm, Rt = 11.53 min, purity = 94%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
59% | With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In N,N-dimethyl-formamide at 60℃; for 8h; Inert atmosphere; | Step 4. Suzuki coupling was carried out by using either palladium (0) or palladium (II). General procedure: Under a nitrogen atmosphere, to a mixture of compound 13 (1 g, 2 mmol, 1 eq), 3,4 - methylenedioxyphenyl boronic acid (0.4 g , 2.46 mmol, 1.2 eq) in DMF (5 mL) was added palladium (0) tetrakis(triphenylphosphine) (0.162 g, 0.14 mmol 0.07 eq). The mixture was stirred at 60 oC for 8 h, diluted with EtOAc, and quenched with saturated NaHCO3. The organic phase was washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by normal phase column (EtOAc in hexane 25%-50%) to yield the desired product (0.92 g, 1.7mmol, 86% yield). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
2.5% | With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In 1,2-dimethoxyethane; ethanol; water at 80℃; for 18h; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium phosphate In 1,2-dimethoxyethane; water |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; sodium carbonate In 1,4-dioxane for 0.333333h; Microwave irradiation; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; caesium carbonate In water; N,N-dimethyl-formamide at 100℃; |
[ 913835-70-8 ]
(4-(5-Methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.98
[ 913835-70-8 ]
(4-(5-Methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.98
[ 276694-22-5 ]
(4-(1,3,4-Oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.97
[ ]
(6-(5-Methyl-1,3,4-oxadiazol-2-yl)naphthalen-2-yl)boronic acid
Similarity: 0.95
[ 2377609-48-6 ]
[3-(5-Ethyl-1,3,4-oxadiazol-2-yl)phenyl]boronic acid
Similarity: 0.92
[ 913835-70-8 ]
(4-(5-Methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.98
[ 276694-22-5 ]
(4-(1,3,4-Oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.97
[ 1072945-71-1 ]
(3-Fluoro-4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.84
[ 913835-70-8 ]
(4-(5-Methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.98
[ 276694-22-5 ]
(4-(1,3,4-Oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.97
[ 1072945-71-1 ]
(3-Fluoro-4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid
Similarity: 0.84